1. Home
  2. MESO vs ANDE Comparison

MESO vs ANDE Comparison

Compare MESO & ANDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • ANDE
  • Stock Information
  • Founded
  • MESO 2004
  • ANDE 1947
  • Country
  • MESO Australia
  • ANDE United States
  • Employees
  • MESO N/A
  • ANDE N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • ANDE Farming/Seeds/Milling
  • Sector
  • MESO Health Care
  • ANDE Industrials
  • Exchange
  • MESO Nasdaq
  • ANDE Nasdaq
  • Market Cap
  • MESO 1.3B
  • ANDE 1.4B
  • IPO Year
  • MESO N/A
  • ANDE N/A
  • Fundamental
  • Price
  • MESO $18.41
  • ANDE $41.29
  • Analyst Decision
  • MESO Buy
  • ANDE Buy
  • Analyst Count
  • MESO 2
  • ANDE 3
  • Target Price
  • MESO $24.00
  • ANDE $51.67
  • AVG Volume (30 Days)
  • MESO 283.4K
  • ANDE 515.3K
  • Earning Date
  • MESO 08-28-2025
  • ANDE 11-03-2025
  • Dividend Yield
  • MESO N/A
  • ANDE 1.89%
  • EPS Growth
  • MESO N/A
  • ANDE N/A
  • EPS
  • MESO N/A
  • ANDE 2.35
  • Revenue
  • MESO $17,198,000.00
  • ANDE $11,539,093,000.00
  • Revenue This Year
  • MESO $288.50
  • ANDE $9.10
  • Revenue Next Year
  • MESO $173.73
  • ANDE $2.78
  • P/E Ratio
  • MESO N/A
  • ANDE $17.57
  • Revenue Growth
  • MESO 191.39
  • ANDE N/A
  • 52 Week Low
  • MESO $7.09
  • ANDE $31.03
  • 52 Week High
  • MESO $22.00
  • ANDE $51.58
  • Technical
  • Relative Strength Index (RSI)
  • MESO 70.00
  • ANDE 59.31
  • Support Level
  • MESO $15.60
  • ANDE $39.16
  • Resistance Level
  • MESO $16.19
  • ANDE $40.66
  • Average True Range (ATR)
  • MESO 0.54
  • ANDE 1.12
  • MACD
  • MESO 0.17
  • ANDE 0.10
  • Stochastic Oscillator
  • MESO 86.95
  • ANDE 92.54

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About ANDE Andersons Inc. (The)

Andersons Inc is a diversified company with its main focus in the agriculture sector. Its operations are segmented into Trade, Renewables, and Nutrient & Industrial. The Trade segment, which generates the majority of the revenue, is engaged in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. Geographically, the company generates the majority of its revenue from the United States and the rest from Canada, Mexico, Egypt, Switzerland, and other markets.

Share on Social Networks: